CurrentProvidence Health PlanPolicy 455

Laboratory Testing Services

Customize your policy alerts

Sign up for Providence Health Plan Policy 455 alerts

Get alerted when Policy 455 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy defines medical necessity, documentation, and coverage criteria for laboratory tests and panels for Providence Health Plan members across commercial and Medicaid/OHP products and guides when tests are considered medically necessary or not.

Policy Summary

PayerProvidence Health Plan

PolicyLaboratory Testing Services

Policy CodePolicy 455

Change TypeNo material changes

Effective DateJun 1, 2026

Last ReviewJun 1, 2026

Next Review DateMar 1, 2027

Key ActionProvide medical records and chart notes (history, exam, treatment plan) and obtain prior authorization for unlisted codes when submitting potentially covered services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7core required criteria for medical necessity (A-G)

Requires validated analytic methodsanalytical validity requirement

Limits repeat testingretesting guidance

6not medically necessary examples

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentProvidence Health PlanPolicy 455

Laboratory Testing Services

Customize your policy alerts

Sign up for Providence Health Plan Policy 455 alerts

Get alerted when Policy 455 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerProvidence Health Plan

PolicyLaboratory Testing Services

Policy CodePolicy 455

Change TypeNo material changes

Effective DateJun 1, 2026

Last ReviewJun 1, 2026

Next Review DateMar 1, 2027

Key ActionProvide medical records and chart notes (history, exam, treatment plan) and obtain prior authorization for unlisted codes when submitting potentially covered services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7core required criteria for medical necessity (A-G)

Requires validated analytic methodsanalytical validity requirement

Limits repeat testingretesting guidance

6not medically necessary examples

Commercial, Medicaid/OHPproduct applicability

Coverage Criteria

inv-01: Medical necessity criteria — Covered when ALL of the following are met

Covered when ALL of the following are met:

General medical necessity criteria: A laboratory test or panel required to prevent, evaluate, diagnose, or treat an illness, injury, disease, or its symptoms may be considered medically necessary when all of the following are met:A-G

A: analytical validity established; B: ordered and performed per manufacturer's indications by a qualified practitioner actively managing care; C: FDA cleared/approved and/or performed in a CLIA-credentialed laboratory appropriate to the method; D: not primarily for convenience; E: type, frequency, extent, site, and duration appropriate for condition; F: not duplicative of other services for same clinical purpose; G: any one of the following - 1) USPSTF Grade A or B for intended use; 2) evidence-based professional society guidance; 3) sufficient published evidence demonstrates change in clinical decision making and improved health outcomes for the member.

inv-02: Not medically necessary — Not medically necessary when ANY of the following apply

Not medically necessary when ANY of the following apply:

Not medically necessary criteria

Lack of analytical validity, inappropriate frequency, or duplication of prior testing without documented clinical change.
Screening in asymptomatic individuals without a USPSTF Grade A or B recommendation or without specific preventive benefit coverage.
Results that will not directly impact clinical management (e.g., would not alter treatment or diagnostic decisions).
Self-referred or member-initiated testing not ordered under the direction of a qualified practitioner.
Non-standard tests (using non-standard methodology or specimen type, broad multi-analyte panels of low/uncertain utility, or reporting in non-recognized units).
Insufficient peer-reviewed evidence to demonstrate safety, effectiveness, or improvement in net health outcomes for the intended use, or absence of FDA authorization for that use.

inv-03: Medical necessity criteria — Covered when ALL of the following are met (additional analytic/clinical validity and evidence pathway requirements)

Covered when ALL of the following are met (additional analytic/clinical validity and evidence pathway requirements):

Analytical validity: The test must demonstrate acceptable analytical validity (accuracy, precision, sensitivity, specificity, reproducibility) using established, validated methods per CLSI/IFCC standards.validated methods and performance

Supported by CLSI and IFCC guidance

Clinical utility: There must be evidence that test results are likely to influence diagnosis or management (i.e., actionable results that change care), consistent with AACC guidance.results alter management

AACC emphasizes utility as prerequisite

Appropriate indication: Testing should be ordered for clinically justified scenarios rather than routine screening in low-risk or asymptomatic populations unless aligned with USPSTF A/B recommendations for preventive screening.

Non-standard tests and tests lacking analytical validity are excluded from coverage. The policy specifies that tests failing to meet established analytic performance (accuracy, precision, sensitivity, specificity, reproducibility) or those not performed in a CLIA‑credentialed, quality‑assured laboratory are considered not medically necessary. Examples include tests that use non‑standard methodologies or specimen types, panels comprised of large numbers of low‑utility analytes, or assays reported in non‑recognized units. The evidence summary highlights that tests lacking validation increase the risk of error and downstream harm, and therefore are excluded from coverage unless analytical validity and clinical utility are demonstrated.

Tests that rely on novel, unvalidated approaches are explicitly excluded. This includes assays based on novel biomarkers, proprietary algorithms, or unconventional specimen types that have not demonstrated analytical and clinical validation. IFCC guidance cited in the policy notes that such methods often produce inconsistent results across laboratories and lack correlation with clinical outcomes; consequently, these non‑standard or unvalidated tests are not supported for coverage until adequate validation and evidence of clinical utility are available.

Screening tests performed in asymptomatic individuals are covered only when aligned with U.S. Preventive Services Task Force (USPSTF) Grade A or B recommendations for the specific population and indication. Screening outside those USPSTF‑recommended indications is considered not medically necessary. The policy also excludes self‑referred or member‑initiated testing that is not ordered under the direction of a qualified practitioner who is actively managing the member's care.

Routine, broad‑based laboratory ordering in low‑risk or asymptomatic populations is regarded as low‑value and generally not medically necessary. CAP evidence summarized in the policy demonstrates that indiscriminate ordering drives downstream cascades (false positives, additional imaging, specialist referrals, invasive procedures) without improving outcomes. The policy therefore restricts testing to clinically justified indications where results are likely to affect diagnosis or management and discourages blanket or routine panels applied to low‑risk populations.

Covered Indications

inv-23: Screening tests with USPSTF Grade A or B recommendations — examples and applicability

Examples and applicability:

USPSTF A/B applicability: Screening laboratory tests are considered medically necessary only when they carry a USPSTF Grade A or B recommendation for the specific population and indication.

Examples of USPSTF-recommended laboratory screenings: Examples include screening for hepatitis B in adolescents and adults at increased risk; screening for prediabetes and type 2 diabetes in adults aged 35-70 years with overweight or obesity; Rh(D) blood typing and antibody screening at first prenatal visit; and colorectal cancer screening in adults aged 45-49 years.

inv-24: Preventive screening tests that receive USPSTF A or B recommendations applied to specified populations (examples: lipid, diabetes, HCV, HIV, syphilis)

Preventive screening tests receiving USPSTF A or B recommendations are covered when applied to the specified populations:

Coding

inv-09: Minimum retesting intervals — implement minimum retesting intervals to avoid redundant testing

Policy instructionImplement minimum retesting intervals to avoid redundant testing; repeat testing within short intervals should be limited unless there is documented clinical change or indication.

RationaleASCLS and quality-improvement studies show repeating tests within short intervals rarely provides new clinically meaningful information and increases unnecessary utilization.

ApplicationRetesting intervals should be enforced by health-system interventions (e.g., hard stops, order defaults) consistent with referenced guidance to reduce duplicate testing.

Documentation requirementWhen repeat testing is requested within short intervals, provide documentation of clinical change or indication supporting the need for retesting.

Provider Actions & Billing Guidance

Prior Authorization

Medical necessity must meet all listed criteria

Tests must meet the policy's medical necessity criteria: demonstrate analytical validity (accuracy, precision, sensitivity, specificity, reproducibility); be ordered and performed per the manufacturer's intended indications by a qualified health care practitioner actively managing the member's care; be FDA cleared/approved and/or performed in a CLIA‑credentialed laboratory appropriate to the method; be appropriate in type, frequency, extent, site, and duration for the member's condition; not be primarily for convenience; not duplicate other services for the same clinical purpose; and meet at least one of: USPSTF Grade A/B for the intended use, evidence‑based professional society guidance, or sufficient published evidence demonstrating the test changes clinical decision making and improves health outcomes.

Provide clinical justification that addresses analytical validity and clinical utility.
Confirm ordering clinician is a qualified practitioner actively managing the member's care.
Document FDA clearance/approval status or CLIA credentialing of the performing laboratory.

Prior Authorization

Recommend prior authorization for unlisted codes

Ordering Requirements

Note

Order tests per manufacturer indications by a qualified practitioner

Tests must be ordered and performed according to the manufacturer's intended indications for use by a qualified health care practitioner who is acting within scope and actively managing the member's care.

Prior Authorization

Ensure clinical justification, documentation, and PA for unlisted codes

Testing must be clinically justified and documented; when submitting unlisted codes for services that could be covered, prior authorization is recommended to avoid denial. Orders should follow evidence‑based indications and adhere to minimum retesting interval guidance.

Document clinical justification and how results will change management
Adhere to minimum retesting intervals and avoid duplicative orders
Obtain prior authorization for unlisted codes tied to potentially covered services

Frequency Limits

inv-25: General frequency guidance — test frequency must be appropriate and not duplicative

General principleTest frequency must be appropriate for the member's condition and not duplicative of other services.

Clinical justificationFrequency should be based on clinical indication, manufacturer's guidance, and evidence that results will impact management.

Avoid routine broad screeningRoutine broad-based laboratory orders in low-risk or asymptomatic populations without evidence of clinical utility are considered low-value.

inv-26: Repeat laboratory tests in short intervals — minimum retesting intervals recommended

Recommended practiceLimit repeat laboratory tests in short intervals; retesting should occur only with documented clinical change or clear indication.

Supporting evidence

Definitions

inv-19: Standard test/panel — definition for standard tests performed in CLIA-certified labs and recognized as clinically valid

DefinitionStandard test/panel: Performed in a CLIA-certified clinical laboratory and recognized as clinically valid by relevant organizations (e.g., CAP, ASCP, AMP, CLSI).

Regulatory contextStandard tests are FDA cleared/approved and/or performed in CLIA-credentialed laboratories appropriate to the method as required for coverage.

Clinical expectationStandard tests must demonstrate analytical validity and clinical utility consistent with policy criteria to be considered medically necessary.

inv-20: Non-standard test — definition including non-standard methodology/specimen, large low-utility analyte panels, or non-recognized units

DefinitionNon-standard test: Uses non-standard methodology or specimen, contains large low-utility analyte panels, or reports in non-recognized units; such tests fail the standard test definition and are not medically necessary.

Not Covered

Not covered examples include tests that are non‑CLIA or otherwise non‑standard in methodology or specimen type, broad multi‑analyte panels of low or uncertain clinical utility, and assays reported in non‑recognized units. The policy states that such non‑standard tests, or tests without demonstrated analytical validity or sufficient peer‑reviewed evidence of safety and effectiveness, will be excluded from coverage because they do not meet the standards required for reliable clinical use.

Non‑standard and unvalidated tests that lack both analytical and clinical validation are not covered. The policy specifically cites examples such as tests based on novel biomarkers, proprietary algorithms, or unconventional specimen types; IFCC guidance and the evidence summary note these approaches frequently lack reproducible performance and demonstrated impact on clinical outcomes, and therefore should be excluded from coverage until sufficient validation and published evidence exist.

Background

Screening differs from diagnostic testing in that it targets asymptomatic populations to detect unrecognized disease or risk. The policy applies an evidence‑based approach: screening is appropriate when the condition is sufficiently prevalent, effective interventions exist, and the test has adequate sensitivity, specificity, and demonstrated benefit (as reflected by USPSTF Grade A/B or other high‑quality guidance). The evidence summary emphasizes that many laboratory tests lack adequate evidence to support screening use and that unnecessary screening in low‑risk populations can lead to harm via false positives and downstream cascades.

Revision History

2026-06-01policy_effectiveLatest

New policy issued (Policy 455) establishing coverage criteria for laboratory testing services, including medical necessity requirements and exclusions for non-standard or unvalidated tests.

Policy Summary

PayerProvidence Health Plan

PolicyLaboratory Testing Services

Policy CodePolicy 455

Change TypeNo material changes

Effective DateJun 1, 2026

Last ReviewJun 1, 2026

Next Review DateMar 1, 2027

Key ActionProvide medical records and chart notes (history, exam, treatment plan) and obtain prior authorization for unlisted codes when submitting potentially covered services.

SourceLink

On This Page

aligned with USPSTF A/B when screening

Refer to USPSTF grades

Non-duplicative/retesting: Repeat testing is limited; retesting within short intervals requires documented clinical indication or change in condition, following ASCLS and minimum retesting interval guidance.documented clinical change or indication

ASCLS and RCPath/CADTH references

Preventive screening — general statement:

Preventive screening laboratory tests that receive USPSTF Grade A or B recommendations are considered medically necessary when applied to the populations and indications specified by USPSTF.

Examples include lipid disorder screening, diabetes screening (HbA1c/glucose) in recommended age and risk groups, hepatitis C, HIV, and syphilis screening in guideline‑recommended populations.

For any unlisted procedure code submitted for a potentially covered service, prior authorization is recommended to avoid post‑service denial; unlisted codes submitted for services that are non‑covered under this policy will be denied as not covered.

Obtain prior authorization before performing or billing for tests reported with unlisted codes when clinical coverage is plausible.
If an unlisted code is submitted without prior authorization and the service is later determined potentially covered, the claim is at risk for post‑service denial.

Step Therapy

No step therapy rules specified

The policy does not specify any step therapy requirements for laboratory testing; no step therapy rules apply per this portion of the policy.

Note

Provider actions — other

(No additional provider actions specified beyond those above.)

Documentation Required

Submit full medical records and chart notes with requests

Provide all medical records and chart notes pertinent to the request, including history, physical examination, and the treatment plan, at the time of the request.

Attach or make available complete history, physical exam findings, and treatment plan documentation to support medical necessity determination.

Billing Rule

Claim‑level review of all unlisted codes

All unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing; documentation supporting medical necessity should be available to prevent denial.

Maintain supporting documentation that demonstrates the test meets medical necessity criteria and coding rationale for claim review.
Be prepared to supply documentation if an unlisted code is submitted so the claim‑level review can determine coverage and pricing.

Denial Risk

Denial triggers — analytic validity, duplication, and inappropriate screening

Requests may be denied when tests lack analytical validity, are duplicative without documented clinical change, are used for screening in asymptomatic individuals without a USPSTF Grade A/B recommendation, will not impact management, are self‑referred/not ordered by a qualified practitioner, are non‑standard, or lack sufficient peer‑reviewed evidence or FDA authorization for intended use.

Avoid ordering non‑standard tests (non‑standard methodology/specimen, broad low‑utility panels, non‑recognized units) without evidence of analytic and clinical validity.
Do not submit screening tests for asymptomatic individuals unless there is a USPSTF Grade A/B recommendation for the intended population.

Denial Risk

Unlisted codes: non‑covered services denied; potentially covered need review/prior authorization

Unlisted codes submitted for services that are non‑covered under this policy will be denied as not covered; unlisted codes for potentially covered services require review and prior authorization is recommended to avoid denial.

If the service falls under the policy's not‑covered criteria (e.g., non‑standard or unvalidated tests), expect denial for unlisted codes.
When coverage may be appropriate, secure prior authorization and retain supporting documentation to demonstrate medical necessity during claim review.

ASCLS and multisite quality-improvement studies report that frequent retesting rarely yields new clinically meaningful information and can cause downstream harms.

Expectation for providersProvide documentation of clinical change or rationale when requesting retesting within short intervals to justify medical necessity.

ExamplesIncludes novel biomarkers, proprietary algorithms, unconventional specimen types, broad low-utility panels, or reporting in non-recognized units.

Coverage stanceNon-standard or unvalidated tests lacking analytical and clinical validation are excluded from coverage per policy.

inv-21: Analytical validity — ability to demonstrate acceptable accuracy, precision, sensitivity, specificity, reproducibility per CLSI

DefinitionAnalytical validity: ability to demonstrate acceptable accuracy, precision, sensitivity, specificity, and reproducibility using established, validated methods per CLSI/IFCC standards.

Evidence requirementPublished, peer-reviewed evidence or validated method-comparison data are required to establish analytical validity prior to coverage consideration.

Risk of poor validityUnvalidated methods, improper calibration, or non-standard specimens increase false-positive/false-negative rates and may compromise clinical decision-making.

inv-22: Clinical utility — evidence that test results directly influence diagnosis, management, or therapy decisions

DefinitionClinical utility: evidence that test results directly influence diagnosis, management, or therapy decisions (i.e., results change clinical decision making and improve outcomes).

Coverage expectationEven analytically valid tests require evidence of clinical utility — tests that do not alter management are low-value and not covered.

Supporting guidanceAACC guidance emphasizes clinical utility as a prerequisite for ordering and reimbursement of laboratory testing.